Arcadia Biosciences, Inc. (RKDA)
USD 3.25
(0.53%)
USD 3.25
(0.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7 Million USD | -12.72% |
| 2022 | 8.02 Million USD | -36.94% |
| 2021 | 12.72 Million USD | -32.32% |
| 2020 | 18.79 Million USD | -22.48% |
| 2019 | 24.24 Million USD | 116.33% |
| 2018 | 11.2 Million USD | 30.9% |
| 2017 | 8.56 Million USD | -75.09% |
| 2016 | 34.37 Million USD | 1.06% |
| 2015 | 34.01 Million USD | 27.05% |
| 2014 | 26.77 Million USD | -0.24% |
| 2013 | 26.83 Million USD | 40.94% |
| 2012 | 19.04 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 5.8 Million USD | 4.31% |
| 2024 Q1 | 5.56 Million USD | -20.55% |
| 2023 Q3 | 8.06 Million USD | -11.03% |
| 2023 Q2 | 9.06 Million USD | -33.9% |
| 2023 FY | 7 Million USD | -12.72% |
| 2023 Q4 | 7 Million USD | -13.21% |
| 2023 Q1 | 13.71 Million USD | 71.0% |
| 2022 Q3 | 9.45 Million USD | 14.75% |
| 2022 Q4 | 8.02 Million USD | -15.16% |
| 2022 FY | 8.02 Million USD | -36.94% |
| 2022 Q1 | 8.55 Million USD | -32.74% |
| 2022 Q2 | 8.24 Million USD | -3.7% |
| 2021 Q4 | 12.72 Million USD | -33.06% |
| 2021 Q3 | 19 Million USD | -32.41% |
| 2021 Q2 | 28.11 Million USD | 12.04% |
| 2021 Q1 | 25.09 Million USD | 33.52% |
| 2021 FY | 12.72 Million USD | -32.32% |
| 2020 Q1 | 20.02 Million USD | -17.42% |
| 2020 FY | 18.79 Million USD | -22.48% |
| 2020 Q4 | 18.79 Million USD | -14.08% |
| 2020 Q2 | 24.16 Million USD | 20.66% |
| 2020 Q3 | 21.87 Million USD | -9.47% |
| 2019 Q4 | 24.24 Million USD | 5.11% |
| 2019 FY | 24.24 Million USD | 116.33% |
| 2019 Q1 | 21.31 Million USD | 90.18% |
| 2019 Q2 | 17.06 Million USD | -19.97% |
| 2019 Q3 | 23.06 Million USD | 35.22% |
| 2018 FY | 11.2 Million USD | 30.9% |
| 2018 Q2 | 23 Million USD | 4.88% |
| 2018 Q1 | 21.93 Million USD | 156.13% |
| 2018 Q4 | 11.2 Million USD | -21.59% |
| 2018 Q3 | 14.29 Million USD | -37.85% |
| 2017 Q1 | 34.27 Million USD | -0.29% |
| 2017 Q2 | 33.67 Million USD | -1.77% |
| 2017 FY | 8.56 Million USD | -75.09% |
| 2017 Q3 | 8.31 Million USD | -75.32% |
| 2017 Q4 | 8.56 Million USD | 3.03% |
| 2016 Q1 | 34.62 Million USD | 1.8% |
| 2016 Q4 | 34.37 Million USD | 0.88% |
| 2016 Q3 | 34.07 Million USD | -1.01% |
| 2016 Q2 | 34.42 Million USD | -0.6% |
| 2016 FY | 34.37 Million USD | 1.06% |
| 2015 Q4 | 34.01 Million USD | -5.87% |
| 2015 FY | 34.01 Million USD | 27.05% |
| 2015 Q3 | 36.14 Million USD | -2.49% |
| 2015 Q1 | 26.71 Million USD | -0.21% |
| 2015 Q2 | 37.06 Million USD | 38.71% |
| 2014 Q3 | 26.75 Million USD | 2.55% |
| 2014 Q4 | 26.77 Million USD | 0.06% |
| 2014 Q2 | 26.09 Million USD | 0.0% |
| 2014 FY | 26.77 Million USD | -0.24% |
| 2014 Q1 | - USD | -100.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 26.83 Million USD | 0.0% |
| 2013 FY | 26.83 Million USD | 40.94% |
| 2012 FY | 19.04 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioceres Crop Solutions Corp. | 501.06 Million USD | 98.603% |
| Muliang Viagoo Technology, Inc. | 9.29 Million USD | 24.694% |
| N2OFF, Inc. | 785.65 Thousand USD | -791.233% |
| Yield10 Bioscience, Inc. | 6.39 Million USD | -9.577% |